CP‐SOCS3 potentially targets the intracellular segments of receptors for leptin, insulin, erythropoietin and G‐CSF.152 These targets may likely be affected upon chronic administration of CP‐SOCS3 rather than during the short‐term treatment of acute injury of the liver (eg fulminant hepatitis) 21 and other organs (eg acute respiratory distress syndrome [ARDS]). Here, SOCS3 is linked to Fulminant hepatitis.